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Chronic heart failure is a major public-health problem with a high prevalence, complex
treatment, and high mortality. A careful and comprehensive analysis is needed to provide optimal
(and personalized) therapy to heart failure patients. The main 4 non-invasive imaging techniques
(echocardiography, magnetic resonance imaging, multi-detector-computed tomography, and
nuclear imaging) provide information on cardiovascular anatomy and function, which form the
basis of the assessment of the pathophysiology underlying heart failure. The selection of imaging
modalities depends on the information that is needed for the clinical management of the patients:
(1) underlying etiology (ischemic vs non-ischemic); (2) in ischemic patients, need for
revascularization should be evaluated (myocardial ischemia/viability?); (3) left ventricular func-
tion and shape assessment; (4) presence of significant secondary mitral regurgitation; (5) device
therapy with cardiac resynchronization therapy and/or implantable cardiac defibrillator (risk of
sudden cardiac death). This review is dedicated to assessment of myocardial viability, however
‘‘isolated assessment of myocardial viability’’ may be clinically not meaningful and should be
considered among all those different variables. This complete information will enable personalized
treatment of the patient with ischemic heart failure. (J Nucl Cardiol 2015;22:229–45.)
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INTRODUCTION
Chronic heart failure has become one of the clinically
most important diseases of the heart. The prevalence is high;
the treatment is complex, and the mortality is significant. The
most detailed report comes from the update of heart disease
and stroke statistics from the American Heart Association1-3
and is discussed in detail in the most recent American Heart
Association/American College of Cardiology guidelines.4
Importantly, 5.1 million patients in the United States
have heart failure, with a rising prevalence. Moreover, it is
indicated that, for the American population, the lifetime
risk of developing heart failure is 20% for individuals of
age 40 years or more.5 Per year, more than 650,000 new
patients are diagnosed with heart failure, and the incidence
increases with increasing age, with more than 80 patients
per 1000 individuals older than 85 years suffering of heart
failure. Per year, more than 1 million patients are hospi-
talized with heart failure as the primary diagnosis, with a 1-
month re-hospitalization rate of 25%.1 The costs for the
care of patients with heart failure is high, exceeding $40
billion per year, with more than 50% of costs allocated to
hospitalizations.1 Finally, the mortality is high, with
approximately 50% of patients surviving 5 years after
being diagnosed with heart failure.1 Specifically, in the
Atherosclerosis Risk in Communities study, the 1- and 5-
year mortality was 10% and 42%, respectively.6,7
It has been pointed out that a careful and compre-
hensive analysis is needed to provide optimal (and
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personalized) therapy to these patients.4,8,9 Most of the
information can be provided by non-invasive imaging.
Currently, the main 4 non-invasive imaging techniques
include echocardiography, magnetic resonance imaging
(MRI), multi-detector-computed tomography (MDCT),
and nuclear imaging (positron emission tomography
[PET] and single-photon emission-computed tomogra-
phy [SPECT]). These imaging techniques can provide
information on cardiovascular anatomy and function,
which form the basis of the assessment of the patho-
physiology underlying heart failure. The selection of
imaging modalities depends on the information that is
needed for the clinical management of the individual
patient. In addition, the choice depends not only on local
availability, but also local expertise and experience with
the modalities and techniques.
The key information that is needed for comprehen-
sive evaluation (for diagnosis and to determine
therapeutic options) is summarized in Table 1. The most
important issue is the etiology underlying heart failure:
this differentiates between ischemic and non-ischemic
cardiomyopathy, which is crucial for therapeutic options.
Most patients will have ischemic cardiomyopathy;
Gheorghiade et al10 summarized the data from 24 trials
published in the New England Journal of Medicine
during the period of 1986-2005, focusing on medical
therapies in heart failure (Figure 1). These trials included
43,568 patients, and the prevalence of coronary artery
disease was 62%; this percentage is probably an under-
estimation, since a significant percentage of patients did
not undergo coronary angiography. Invasive coronary
angiography remains the modality of choice to visualize
the coronary arteries and detect or exclude coronary
atherosclerosis/stenosis. However, non-invasive imaging
modalities (MRI, MDCT) can also visualize the coronary
arteries and detect coronary stenoses. MRI has been used
extensively for coronary artery imaging. Particularly
MDCT coronary angiography has been increasingly used
for non-invasive angiography with a very high diagnostic
accuracy: a recent meta-analysis with 89 studies and
7,516 patients showed a sensitivity of 97.2% and a
specificity of 87.4%.11 MDCT coronary angiography has
also been used successfully in patients with heart failure
of unknown etiology,12 but it should be stressed that
many patients with heart failure have elevated heart rate,
whereas for MDCT coronary angiography low heart rates
(\60 beats per minute) are needed.
In patients with ischemic cardiomyopathy, the need
for revascularization needs to be considered and assess-
ment of ischemia and viability is required. Next, the
function, the size and the shape of the left ventricle need
to be assessed: function is important for prognosis and
potential indication for device therapy, whereas assess-
ment of shape is important to evaluate the presence of
severe left ventricular (LV) aneurysms. Also, patients
with severe heart failure often have secondary mitral
regurgitation: the prevalence of moderate or severe
secondary mitral regurgitation in heart failure patients
ranges between 24% and 30% and is associated with
poor prognosis.13,14 If severe mitral regurgitation is
present, mitral valve repair should be considered.
Finally, patients with severe heart failure should be
considered for device therapy, i.e., implantable cardiac
defibrillator (ICD) device with or without cardiac
resynchronization therapy (CRT). The need for these
devices is based mainly on the LV ejection fraction (EF)
and the duration of the QRS complex on the electrocar-
diogram (ECG), but imaging techniques may provide
additional information that may be useful to improve
patient selection.
This chapter is dedicated to assessment of myocar-
dial viability, but the summary above already indicates
that ‘‘isolated assessment of myocardial viability’’ is
clinically not meaningful and should be considered
among all the different variables that are summarized in
Table 1. This complete information will enable person-




Chronic contractile dysfunction can not only be
related to scar tissue, but can also be related to
hibernation or chronic stunning. In the presence of scar
tissue, recovery of function will not occur, but in
hibernation or chronic stunning, recovery of function
may occur after revascularization. Viable myocardium is
generally referred to as ‘‘alive myocardium,’’ indepen-
dent of the contractile status of the myocardium. This
however may not be preferred in the clinical setting,
since the aim is to eventually predict improvement of
function post-revascularization. Accordingly, the start-
ing point in the discussion on viability should be the
identification of regional dysfunction (usually assessed
by echocardiography, but can also be detected by MRI
or MDCT).
The distinction between hibernation and chronic
stunning can be based on the assessment of myocardial
blood flow; in hibernation resting blood flow is reduced,
whereas in chronic stunning resting flow may still be
preserved but flow reserve will be reduced.15 Clinically
this differentiation may not always be feasible, but may
also not be needed, since both entities require revascu-
larization to improve in function and can be referred as
viable, ischemically jeopardized myocardium.
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In contrast, the mixture of normal (non-jeopardized)
myocardium and scar tissue (as may be encountered
with subendocardial scar formation) will not improve in
function and can be considered as viable, non-jeopar-
dized myocardium (Figure 2).16
Imaging Techniques to Detect Myocardial
Viability—General Issues
A variety of non-invasive imaging techniques have
been developed to detect viable myocardium in patients
with ischemic heart failure. The different imaging
techniques target different characteristics of viable
myocardium (Table 2) and thus provide different infor-
mation, which translate in different accuracies to predict
improvement of function after revascularization.17
Most experience has been obtained with nuclear
imaging using SPECT and PET; both techniques permit
assessment of cardiac metabolism and perfusion. With
SPECT, cell membrane or mitochondrial integrity can
also be assessed.
Resting echocardiography or MRI can be used to
assess LV end-diastolic wall thickness; it has been
demonstrated that thinned myocardium (\6 mm) does
not often improve in function after revascularization.18
Both echocardiography and MRI can be used in com-
bination with low-dose dobutamine infusion to detect
contractile reserve in dysfunctional myocardium. All
these techniques aim at the detection of viability. It has
been demonstrated that 40-50% of dysfunctional
segments without contractile reserve may still have
preserved perfusion and/or metabolism; some of these
segments may still recover function after revasculariza-
tion. It has been shown that loss of contractile reserve is
associated with more severe ultrastructural damage and
fibrosis formation and the severity of damage may
eventually determine whether functional recovery is still
possible.
In contrast to all the techniques discussed above
which detect viable myocardium, contrast-enhanced
MRI is the technique of choice, with the highest
resolution, to detect scar tissue.
The Different Imaging Techniques to Detect
Viability
Most protocols and techniques have been described
extensively over the last decades and have become
widely implemented in the clinical setting.17
Figure 1. Heart failure etiology. From 24 multicenter heart
failure trials, including 43,568 heart failure patients, 62% of









Figure 2. Prediction of functional recovery post-revascular-
ization in dysfunctional segments with subendocardial scar is
difficult. When the epicardial (non-infarcted) region is normal,
no recovery will occur (left panel). However when the
epicardial region contains jeopardized (viable) myocardium,
the likelihood of recovery is high (right panel). Reproduced
with permission from Kaandorp et al16.
Table 1. Information needed in patients with heart failure
Etiology: ischemic or non-ischemic heart failure?
Revascularization needed: is there ischemia and/or viability?
LV function, LV size and LV shape (LV aneurysm?)
Mitral valve: is there severe secondary mitral regurgitation?
Is ICD and/or CRT needed?
CRT, cardiac resynchronization therapy; ICD, implantable cardiac defibrillator; LV, left ventricular
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Positron emission tomography. Various
PET tracers have been used (oxygen15-labeled water,
carbon11-acetate, rubidium82), but for viability assess-
ment, most experience has been obtained with metabolic
imaging using fluorine18-deoxyglucose (FDG). This
tracer is a glucose analog (1 OH-group is replaced by
an F18 atom) and reflects cardiac glucose utilization.
The first cellular uptake is comparable to glucose, and
after phosphorylation to FDG-6-PO4, the tracer remains
in the myocyte, which provides a strong signal for
imaging. Since cardiac FDG uptake is strongly affected
by metabolic circumstances, strict standardization of the
metabolic milieu (plasma levels of glucose, free fatty
acids, and insulin) is needed. To maximize cardiac
glucose uptake, low free fatty acid levels with high
glucose and insulin levels are required. This can be
achieved with hyperinsulinemic euglycemic clamping,
but this approach is time-consuming; alternative ap-
proaches include oral glucose loading and the use of
nicotinic acid derivatives.
FDG imaging is combined with assessment of
perfusion (usually nitrogen13-ammonia), and different
patterns can be observed in areas of contractile dys-
function. Viable tissue may show normal perfusion and
FDG uptake (which reflects chronic stunning) or re-
duced perfusion and preserved FDG uptake (referred to
as mismatch pattern, which reflects hibernation). Scar
tissue is characterized by reduced (non-transmural scar)
or absent perfusion and FDG uptake (transmural scar).
Of note, FDG imaging with SPECT and 511 keV
collimators has also been developed successfully over
the last decades (Figure 3).19
Single-photon emission-computed to-
mography. Both 201thallium chloride and
99technetium labelled SPECT tracers have been used.
Following intravenous injection, the initial uptake of
201thallium predominantly reflects myocardial perfusion,
and the prolonged retention/uptake reflects cell
membrane integrity. Both stress-redistribution-reinjec-
tion and rest-redistribution protocols have been used in
the clinical setting. Both protocols provide information
on viability, whereas the first protocol includes also
information on stress-inducible ischemia.
Various patterns of viability have been recognized
in areas of contractile dysfunction, but they can be
simplified as follows: any region with [50% tracer
uptake on a resting image, and any defect with [10%
increase in tracer uptake on the delayed images.20 It is
however important to note that regions with [50%
tracer uptake often do not improve in function, since
these regions often contain a mixture of normal tissue
and non-transmural scar.
The uptake and retention of the technetium-based
tracers depend on perfusion, cell membrane integrity,
and mitochondrial function. In areas of contractile
dysfunction, a [50-60% tracer uptake on a resting
image is frequently used as marker for viability. It has
also been proposed to perform 99technetium sestamibi
SPECT after nitrate administration, in order to increase
blood flow (and tracer delivery) to severely hypoper-
fused areas.20 Typically, a resting image and a nitrate-
enhanced image are acquired, and [10% increase in
tracer uptake on the nitrate-enhanced images is consid-
ered indicative of viability.
Dobutamine stress echocardiogra-
phy. During stepwise infusion of dobutamine,
echocardiographic images are obtained evaluating re-
gional wall motion. The initial phase includes low-dose
dobutamine (5 to 10 mcg/kg/min) infusion, and the hall-
mark of viability is ‘‘contractile reserve’’ which is
improvement of contractile dysfunction during low-dose
dobutamine infusion. The protocol can be extended to
high-dose dobutamine infusion (up to 40 mcg/kg/min
with addition of atropine), which allows detection of
ischemia. The different wall motion responses during
low–high dose dobutamine include (A) biphasic
Table 2. Different characteristics of viable myocardium assessed with different imaging techniques
Imaging modality Viability marker
Nuclear imaging
SPECT using Tl-201 Perfusion, cell membrane integrity
SPECT using Tc-99m tracers Perfusion, cell membrane integrity, intact mitochondria
PET (or SPECT) with FDG Glucose utilization
Echocardiography
Low-dose dobutamine infusion Contractile reserve
MRI
Low-dose dobutamine infusion Contractile reserve
Intravenous contrast agents Scar tissue
FDG, fluorine18-deoxyglucose; MRI, magnetic resonance imaging; Tc-99m, 99technetium; Tl-201, 201thallium
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response (initial improvement followed by worsening of
wall motion), (B) immediate worsening (direct dete-
rioration of wall motion without initial improvement),
(C) sustained improvement (improvement of wall mo-
tion without subsequent deterioration), and (D) no
change (no change in wall motion at any stage). Pattern
A represents viability with superimposed ischemia;
pattern B represents severe ischemia due to critical
coronary artery stenosis; pattern C relates to subendo-
cardial infarction, and pattern D indicates transmural
scar formation.
Magnetic resonance imaging. Areas with
contractile dysfunction and a very thinned wall
(\6 mm end-diastolic wall thickness) have a low like-
lihood of viability and functional recovery. Conversely,
dysfunctional regions with preserved wall thickness do
not always improve in function, and this is related to the
presence of subendocardial scar (and the remainder of
the wall being normal). Contractile reserve can be
detected with MRI during dobutamine infusion as
described above with echocardiography. An advantage
of MRI is that wall thickening and motion can be
quantitatively assessed, although in the clinical practice
this rarely happens. The main contribution of MRI is the
use of gadolinium-based contrast agents to detect scar
tissue. Based on the excellent spatial resolution, con-
trast-enhanced MRI can differentiate between non-
transmural and transmural scar tissue (Figure 4).
Prediction of Functional Recovery After
Revascularization
A recent, very extensive report summarized the
results of the viability studies focusing on prediction of
functional recovery, and the results are summarized in
Figure 5, and Tables 3 and 4.17
The highest sensitivity was obtained by FDG PET
(92%), followed by SPECT with thallium-201 (87%)
and technetium-99m-labeled agents (83%). The most
specific approach was dobutamine stress echocardiogra-
phy (specificity 78%). Improvement of global LV
function (LVEF) is clinically more meaningful than
Figure 3. Example of a 76-year-old patient with previous anterior myocardial infarction and 2-
vessel coronary artery disease on invasive coronary angiography (significant long lesion on the
proximal left anterior descending coronary artery and dominant circumflex coronary artery with a
significant lesion proximal). Left ventricular ejection fraction was 27%. Selected short-axis views
of myocardial perfusion 99technetium tetrofosmin SPECT images show a perfusion defect in the
anteroseptal wall. On fluorine18-deoxyglucose (FDG) SPECT images segments, uptake of
radiopharmaceutical in the anteroseptal wall is visualized indicating perfusion-metabolic mismatch,
pattern of myocardial viability.
Figure 4. Contrast-enhanced magnetic resonance imaging for
characterization of myocardial scar. Selected 4-chamber views
on contrast-enhanced MRI of two patients with ischemic
cardiomyopathy show non-transmural subendocardial scar (A
arrow) and transmural scar (B arrow).
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improvement of segmental function. It is unclear how
much viable myocardium is needed to result in the
improvement of global LV function. Various studies
have shown that recovery of global LV function may
occur when at least 25% of the dysfunctional segments
are viable.21-27 It should be emphasized however that
various other factors also influence recovery of function
(these are discussed below). Not only improvement of
function is important, but also improvement in exercise
capacity and heart failure symptoms are relevant,
particularly from a patient’s perspective. This has been
addressed in 8 studies,22,23,28-33 and the pooled analysis
Figure 5. Comparison of sensitivities and specificities with 95% confidence intervals of the
various techniques for the prediction of recovery of regional (A) and global (B) left ventricular
function following coronary revascularization. Data based on Schinkel et al17. Echo, echocar-
diography; FDG, fluorine18-deoxyglucose; MRI, magnetic resonance imaging; PET, positron
emission tomography; Tc-99m, 99technetium; Tl-201, 201thallium.
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indicated that patients with significant viable tissue
revealed an improvement in New York Heart Asso-
ciation (NYHA) functional class from 2.9 to 1.6 after
revascularization, whereas the NYHA class did not
change significantly in patients without viable tissue. In
addition, 3 studies evaluated exercise capacity (ex-
pressed in METS) in relation to viability on FDG
PET;21,34,35 in the viable patients, the exercise capacity












(756 patients, 24 studies)
92 (1025/1111) 63 (620/984) 74 (1025/1389) 87 (620/716)
Tl-201
(1119 patients, 40 studies)
87 (2559/2931) 54 (1431/2655) 67 (2557/3810) 79 (1431/1814)
Tc-99m
(721 patients, 25 studies)
83 (1170/1414) 65 (778/1189) 74 (1170/1581) 76 (778/1022)
DSE
(1421 patients, 41 studies)
80 (3163/3941) 78 (3708/4746) 75 (3142/4174) 83 (3729/4518)
MRI wall thickness
(100 patients, 3 studies)
95 (264/277) 41 (144/354) 56 (264/474) 92 (144/157)
MRI dobutamine
(272 patients, 9 studies)
74 (564/766) 82 (720/878) 78 (564/722) 78 (720/923)
CE-MRI
(178 patients, 5 studies)
84 (892/1060) 63 (610/964) 72 (892/1247) 78 (610/778)
CE, contrast-enhanced; DSE, dobutamine stress echocardiography; FDG, Fluorine18-deoxyglucose; MRI, magnetic resonance
imaging; NPV, negative predictive value; PPV, positive predictive value; Tc-99m, 99technetium; Tl-201, 201thallium
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improved from 4.4 to 5.7 after revascularization, where-
as the change was minimal in non-viable patients (from
5.1 before to 5.9 after revascularization).
The most important issue is however the impact of
viability on prognosis. A total of 28 retrospective
viability studies have been reported including 3848
patients.17 The annualized mortality was lowest in the
viable patients who underwent revascularization (3.6%),
whereas annualized mortality was comparable in the
other groups (ranging from 9.1% to 11.6%) (Figure 6).
These retrospective studies suggested a direct relation
between viability, improvement of function post-revas-
cularization, translating in improved outcome. This
topic was subsequently addressed in 1 prospective,
randomized controlled trial: the STICH (Surgical Treat-
ment for Ischemic Heart Failure) trial.36 In the larger
part of the trial, 1212 patients with LVEF B 35% and
chronic coronary artery disease amenable to surgical
revascularization were randomized to medical therapy
(n = 602) or medical therapy and coronary artery
bypass grafting surgery (CABG) (n = 610). In the
medically treated group, death or hospitalization for
cardiovascular events occurred in 411 patients (68%), as
compared to 351 (58%) in the CABG group (hazard
ratio with CABG, 0.74; 95% confidence interval, 0.64 to
0.85; P \ 0.001). In the substudy, including 601 patients
(298 medical therapy and CABG, 303 medical therapy
alone), the relation between viability, therapy (surgery
or medical therapy), and outcome was evaluated.37 The
mortality was less in the viable patients (37%) as
compared to the non-viable patients (51%, hazard ratio
for death among patients with viable myocardium, 0.64;
95% confidence interval, 0.48 to 0.86; P = 0.003).
Importantly, following correction for other baseline
variables, this association with mortality was not sig-
nificant (P = 0.21): these variables included LVEF, LV
volumes, severity of symptoms, all indicators of more
severe disease. In addition, there was no significant
interaction between viability status and treatment re-
garding mortality (P = 0.53). Various issues could have
affected the results of the STICH trial. First, as was
pointed out in the beginning of this chapter, the focus
should be on dysfunctional segments and in the STICH
analysis all segments were included, and a large per-
centage of segments may be viable but have normal
contractile function (and these cannot improve in
function, and may thus affect the current results). This
is also reflected in the distribution between viable and
non-viable patients: 487 vs 114, while in the daily
practice, the majority of patients with previous infarc-
tion does not contain viability in the infarcted area. In
the current trial, the small cohort of non-viable patients
is then randomized to 60 patients receiving medical
therapy and 54 undergoing CABG. In addition, the
viability techniques used were dobutamine stress
echocardiography and 99technetium SPECT imaging,
whereas FDG PET (the most sensitive viability assess-
ment technique) and contrast-enhanced-MRI (the most
accurate scar assessment technique) may have been
preferred. Probably the most important issue is the
beginning of this article: viability is only one part of the
diagnostic and prognostic work-up of the patients with
ischemic heart failure, and all other factors indicated in
Table 1 will affect outcome. In the 2014 European
Society of Cardiology guidelines on myocardial revas-
cularization, it is recommended that myocardial
revascularization should be considered in patients with
chronic ischemic heart failure (LVEF B 35%) in the
presence of viable myocardium (class IIA, level of
evidence B).38
Other Information Needed in Chronic
Ischemic Heart Failure: LV Function, Size,
and Shape
Left ventricular volumes and LVEF are important
parameters for the risk stratification and management
(particularly device therapy) of heart failure patients.
The wide availability, accuracy, and safety make 2-
dimensional transthoracic echocardiography the imaging
technique of first choice (video 1).9 Besides LV dimen-
sions, geometry, and LVEF, echocardiography provides
information on diastolic function, valvular heart disease,
pericardial disease, right ventricular function, and pul-
monary systolic pressure. Internal LV linear dimensions
can be measured from M-mode recordings from the
parasternal long-axis view which is a reproducible and
high temporal resolution method. However, in abnormal
LV geometry, these measurements are not accurate, and
Figure 6. Annualized mortality rate of patients with and
without significant viable myocardium according to treatment
strategy. Results of a pooled analysis from 28 prognostic
studies using different imaging techniques. Patients with viable
myocardium who underwent coronary revascularization had
the lowest mortality rate. Data based on Schinkel et al17.
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assessment of LV volumes using the biplane disk
summation method from the apical 2- and 4-chamber
views is recommended (Figure 7).39 The addition of
intravenous echocardiographic contrast is recommended
when C2 contiguous LV endocardial segments are
poorly visualized (video 1). These contrast agents
enhance endocardial border definition and provide more
reproducible measurements of volumes and LVEF,
and compare well with MRI.40 Further improvement
can be obtained by 3-dimensional echocardiography
(Figure 7).41 Besides echocardiography, other 3-dimen-
sional techniques such as MRI42 or ECG-gated MDCT
provide high-quality measurements of LV volumes and
LVEF (Figure 7, video 1).43 Finally, with ECG-gated
myocardial perfusion SPECT accurate 3-dimensional
measurements of LV volumes and EF can be obtained
from the time volume curves (Figure 7).
In addition, LV shape is important, and particularly
the formation of large LV aneurysms after infarction.
Thrombus formation frequently occurs at these aneurys-
matic sites, and surgical resection of dysfunctional
myocardium and/or scar tissue can reduce LV size and
restore normal geometry.38 Information on location and
extent of LV aneurysms can be provided by echocar-
diography, MRI, MDCT, and gated SPECT (Figure 8,
video 1).
Additional Information: Severe Secondary
Mitral Regurgitation
Secondary mitral regurgitation occurs frequently in
patients with ischemic heart failure, and is characterized
by a combination of reduced LV closing forces (due to
LV dysfunction or dyssynchrony) and global and
regional LV remodeling which leads to distortion of
the subvalvular apparatus of the mitral valve, displace-
ment of the papillary muscles, tethering of the mitral
leaflets, and failure of mitral valve coaptation. Se-
condary mitral regurgitation results in LV volume
overload, which further worsens LV remodeling and
mitral valve incompetence. The presence of significant
secondary mitral regurgitation provides incremental
prognostic information over LVEF.13 In 1256 heart
failure patients (60% ischemic etiology), significant
secondary mitral regurgitation was associated with
increased risk of heart failure hospitalization and all-
cause mortality.13 Therefore, accurate quantification of
secondary mitral regurgitation severity is crucial for
clinical decision making in heart failure patients. Two-
dimensional echocardiography remains the mainstay
imaging technique to assess the severity and mechanism
of secondary mitral regurgitation.44 Severe secondary
mitral regurgitation is defined by an effective regurgitant
orifice area C0.2cm2 and a regurgitant volume C30 mL/
beat quantified using the proximal isovelocity surface
area (PISA) method.44 While in central regurgitant jets,
the PISA method is relatively accurate to quantify the
severity of mitral regurgitation, in eccentric or multiple
regurgitant jets or non-hemispheric regurgitant orifices,
this method may be less accurate (Figure 9, video 2). In
those cases, 3-dimensional imaging techniques may
provide more accurate quantification of secondary mitral
regurgitation severity (Figure 9, video 2).45 Further-
more, secondary mitral regurgitation is highly dynamic
and strongly influenced by pressure and volume condi-
tions. Therefore, in symptomatic heart failure patients
with mild to moderate secondary mitral regurgitation,
exercise echocardiography may help unmask severe
mitral regurgitation. An increase in effective regurgitant
orifice area C0.13 cm2 at peak stress has been associated
with poor survival.46
The suitability for surgical restrictive mitral valve
annulopasty is influenced by several geometrical aspects
of the mitral valve and left ventricle, and also by the
presence of extensive myocardial scar, which has been
associated with increased mortality rates after surgical
repair.47,48
More Information: Sudden Cardiac Death
Patients with ischemic heart failure and depressed
LVEF (B35%) have an increased risk of arrhythmic
death.49 Various trials have demonstrated the prophy-
lactic benefit of an ICD in these patients.50-53 However,
the percentage of patients that require ICD therapy
(appropriate shocks) to prevent ventricular tachycar-
dia/fibrillation (VT/VF) at follow-up is relatively low,
suggesting that a substantial percentage of patients may
not benefit from ICD.54 Currently, the LVEF (\30-35%)
is used as the main selection criterium for ICD
therapy.55 The precise substrate for VT/VF however is
unknown, but may be related to scar tissue (infarct zone)
and the heterogenous border zone around the infarct
core (mixture of viable myocardium interspersed with
fibrous and scar tissue). Non-invasive imaging may
eventually help in patient selection for ICD implanta-
tion. The presence, extent, and characteristics of
myocardial scar assessed with contrast-enhanced MRI
have incremental prognostic value over LVEF to predict
the occurrence of VT/VF.56 Subsequent studies quanti-
fying the extent of contrast-enhanced tissue (scar mass)
revealed that the arrhythmic risk increased significantly
when the scar mass exceeded [1.4-5% of the LV
volume (Figure 10).57,58 However, this arrhythmic risk
reached a plateau at larger levels of scar mass suggesting
that other factors contribute to the arrhythmogenic
substrate, and the extent of the border zone has also
been associated with increased risk of VT. Roes et al59
Journal of Nuclear Cardiology Bax and Delgado 237
Volume 22, Number 2;229–45 Myocardial viability in ischemic HF
demonstrated that an extent of the border zone C16.7 g
identified a group of patients with high incidence of
appropriate ICD therapies. Each 10 g increase of border
zone increased the risk of appropriate ICD therapies by
1.49 (95% confidence interval 1.01-2.2, P = 0.04)
independently of LVEF and extent of infarct core.59
Possibly, another characteristic of the border zone is
the presence of viable but (partially) denervated my-
ocardium; the functional integrity of the sympathetic
nerve terminals in this area can be evaluated with using
radiolabeled norepinephrine analogs.60 This concept was
recently addressed in the Prediction of ARrhythmic
Events with Positron Emission Tomography trial.61 In
204 heart failure patients receiving an ICD, cardiac
sympathetic innervation was quantified with 11C-meta-
hydroxyephedrine (11C-HED) PET, perfusion was
assessed with 13nitrogen-ammonia and viability was
quantified with FDG. Patients with vs without ICD
shocks had significantly larger areas of denervated
myocardium (33 ± 10% vs 26 ± 11%, P \ 0.001) and
larger areas of denervated, viable myocardium (10 ± 6%
vs 7 ± 5%, P = 0.02) despite having comparable LVEF.
In addition, the extent of denervated myocardium was
independently associated with ICD shocks (hazard ratio
1.069 per 1% increment, 95% confidence interval 1.023-
1.117; P = 0.003).61 Similarly, 123-iodine (123I)-
Figure 7. Assessment of left ventricular systolic function and geometry with current imaging
modalities. A 2-dimensional transthoracic echocardiography; B 3-dimensional transthoracic
echocardiography; C magnetic resonance imaging; D multi-detector row computed tomography;
E ECG-gated single-photon emission-computed tomography.
Figure 8. Example of a patient with large anterior myocardial infarction and subsequent formation
of a large apical aneurysm. On transthoracic 2D echocardiography (A), the arrow points to the large
apical aneurysm with thrombus formation. Magnetic resonance imaging shows a thin-walled apical
aneurysm (arrow) extending from the mid septum to the apical lateral wall (B). On contrast-
enhanced MRI (C), the short-axis view of the aneurysm shows hyperenhanced transmural scar
(white) with a large apical thrombus (black, arrow).
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metaiodobenzylguanidine (MIBG) SPECT has been
used to evaluate cardiac innervation. From the planar
images, the heart-to-mediastinum (H/M) ratio and the
washout rate quantify the global myocardial uptake of
123I-MIBG (Figure 11). The AdreView Myocardial
Imaging for Risk Evaluation in Heart Failure trial,
enrolling 961 heart failure patients (68% ischemic heart
disease), showed that an H/M ratio \1.6 identified a
cohort of patients with increased incidence of ven-
tricular arrhythmias.62 The H/M ratio was an
independent predictor of cardiac events (hazard ratio
0.36, 95% confidence interval 0.17-0.75; P = 0.006). In
addition, from SPECT images, regional abnormalities in
123I-MIBG uptake have been associated with ventricular
Figure 9. Assessment of secondary mitral regurgitation. Example of a 56-year-old patient with
previous inferior myocardial infarction and chronically occluded right coronary artery who
presented with dyspnea on exertion. On transthoracic color Doppler echocardiography, severe
mitral regurgitation with an eccentric jet (green) adhering to the lateral left atrial wall and reaching
the pulmonary veins (due to restriction of the posterior mitral leaflet) is shown (A left). Continuous
wave Doppler shows a holosystolic dense signal of the regurgitant jet (A right). On transesophageal
echocardiography, the lack of coaptation between the leaflets can be appreciated leading to large
regurgitant jet on color Doppler view (B). On 3-dimensional transesophageal echocardiography, the
en-face view of the mitral valve shows lack of coaptation at all the segments of the mitral leaflets
(left) and the multiplanar reconstructions of the 3-dimensional color Doppler data show a large
elongated effective regurgitant orifice (C right).
Journal of Nuclear Cardiology Bax and Delgado 239
Volume 22, Number 2;229–45 Myocardial viability in ischemic HF
arrhythmias.63 Among 116 ICD recipients (74% is-
chemic heart failure), a late 123I-MIBG SPECT summed
defect score [26 identified a subgroup of patients with
high cumulative rates of ventricular arrhythmias at
3 years follow-up (52% vs 5%, P \ 0.01).63 These
studies suggest that imaging may potentially help in
patient selection for ICD therapy.
Final Information: Cardiac
Resynchronization Therapy
Cardiac resynchronization therapy can also improve
clinical outcomes of heart failure patients in NYHA
functional class II-IV despite optimal medical therapy,
with LVEF \35% and QRS duration [120 ms.64 The
individual response varies significantly and imaging
may help improve patient selection. Nuclear imaging
techniques provide information on 2 important patho-
physiological determinants of response to CRT: LV
mechanical dyssynchrony65-67 and the extent and loca-
tion of LV scar tissue.66,68,69
Phase analysis measures the onset of mechanical
contraction by approximating the variation of regional
maximal counts over the cardiac cycle (which represents
myocardial wall thickening) in SPECT myocardial perfu-
sion imaging with Fourier harmonic functions
(Figure 12).70 From the onset mechanical contraction phase
distribution, the phase standard deviation and the phase
Figure 10. Myocardial scar and viability for assessment of risk of arrhythmic death. Example of a 57-year-old patient with anterior
myocardial infarction and a left ventricular ejection fraction of 17%. Contrast-enhanced magnetic resonance images show large
transmural scar in the anterior and septal walls and subendocardial (50% of the wall) in the inferoseptal wall. Selected vertical and
horizontal long-axis and short-axis views of the left ventricle on 99mTechnetium tetrofosmin SPECT show a perfusion defect of the
septal, anterior and apical segments that match the defects on fluorine18-deoxyglucose SPECT. The patient received an implantable
cardiac defibrillator (ICD) for primary prevention of sudden cardiac death. Two months later, the patient was admitted with an
appropriate ICD shock.
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histogram bandwidth are derived as quantitative indices of
LV mechanical dyssynchrony. The relevance of these LV
mechanical dyssynchrony indices to predict response to
CRT was demonstrated in 40 patients with heart failure
(70% ischemic cardiomyopathy).65 After 6 months of
follow-up, 60% of patients revealed a symptomatic im-
provement (responders). Compared with non-responders,
these patients had significantly larger histogram bandwidth
(94 ± 23 vs 68 ± 21, P\ 0.01) and phase standard
deviation (26 ± 6 vs 18 ± 5, P \0.01). Furthermore,
accumulating evidence has shown that an LV lead placed at
the latest activated region of the left ventricle is associated
with good response to CRT.71 The phase polar maps of the
left ventricle can be subdivided into 17 segments and the
mean phase of each segment, which represents the timing of
onset of mechanical contraction, can be displayed. The
segment with the largest mean phase is identified as the latest
activated segment. Furthermore, the presence of transmural
Figure 11. Cardiac innervation imaging with 123-iodine (123I)-
metaiodobenzylguanidine (MIBG). The planar images show
the global myocardial uptake (red circles) of 123I-MIBG of two
patients with ischemic heart failure: patient A had a heart-to-
mediastinum (H/M) ratio of 1.54, indicating low cardiac MIBG
uptake, while patient B had an H/M ratio of 1.64, indicating
more preserved MIBG uptake. Both patients received an
implantable cardiac defibrillator (ICD). At follow-up, only
patient A had appropriate ICD shocks while patient B
remained free of ventricular arrhythmias.
Figure 12. Phase analysis of ECG-gated SPECT myocardial perfusion imaging to assess LV
dyssynchrony. From the reconstructed and reoriented ECG-gated SPECT myocardial perfusion
imaging data, a gated short-axis image is obtained. On each temporal frame of the gated short-axis
image, 3-dimensional sampling is performed to detect the regional maximum counts which
represent regional wall thickening data. The first harmonic Fourier function is used to approximate
the regional wall thickening data to calculate the phase angle for each region. From the regional
phase angles, the phase distribution is derived and presented in a polar map or a histogram.
Reproduced with permission from Chen et al70.
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scar at the segments targeted by the LV lead and the presence
of significant scar burden have been associated with lack of
response to CRT.68,69
Eventually, the information on LV dyssynchrony,
the site of latest activation, and scar tissue can be fused
with fluoroscopic venograms into a 3-dimensional LV
epicardial surface extracted from ECG-gated SPECT
myocardial perfusion imaging (Figure 13).72 The clin-
ical role of this tool needs to be demonstrated in
prospective studies, but it highlights the potential use of
nuclear imaging to select patients for CRT.
CONCLUSION
The patient with ischemic heart failure needs careful,
stepwise diagnostic analysis; non-invasive imaging can
provide much of this information. Myocardial viability
assessment is an important component, but should be
integrated within all other relevant information. Once all
the information is completed, a personalized therapeutic
plan can be presented, making a personalized approach
feasible to the individual patient.
CASE 1
A 59-year-old male presented at the outpatient
clinic with heart failure symptoms since 3 weeks. The
patient was a smoker and had hypertension treated with
angiotensin converting enzyme inhibitors. On transtho-
racic echocardiography, a dilated left ventricle with a
biplane left ventricular ejection fraction of 22% and
global hypokinesia were observed (video 1). The inva-
sive coronary angiography showed severe 3-vessel
coronary artery disease (video 2). To assess the presence
of viable myocardium, magnetic resonance imaging was
requested. On cine acquisitions, the left ventricular end-
diastolic and end-systolic volumes were 420 mL and
348 mL, respectively, and the left ventricular ejection
fraction was 17 % (video 3). The end-diastolic wall
thickness was [6 mm. On contrast-enhanced magnetic
resonance imaging, subendocardial scar \10 % of the
mid anterior and inferior walls was documented (Figure
1, arrows). In addition, low-dose dobutamine stress
echocardiography was performed showing the sig-
nificant increase in wall thickness and left ventricular
function (video 4). Detection of ischemia with a higher
dose of dobutamine was not performed. Based on the
magnetic resonance and low-dose dobutamine stress
echocardiography findings (end-diastolic wall thickness
[6 mm and subendocardial scar of \10 %, improve-
ment of left ventricular systolic function during
dobutamine) indicating the presence of myocardial
viability, the patient was referred for surgical revascu-
larization. Echocardiography at 1 year follow-up
Figure 13. Fusion imaging of cardiac venous anatomy and left ventricular site of latest activation
to guide left ventricular lead position. The SPECT-vein navigation tool kit permits fusion imaging
of fluoroscopic venograms into a 3-dimensional LV epicardial surface extracted from ECG-gated
SPECT myocardial perfusion imaging (A). The mid part of the anterior vein (AV, blue line) was
aligned with the optimal site (white segment). B shows the final position of the LV lead on the left
anterior oblique (LAO) and right anterior oblique (RAO) projections. C shows the post-
implantation ECG with significant reduction of the QRS duration when CRT was activated (from
168 to 140 ms). Reproduced with permission from Zhou et al72.
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showed reduction of left ventricular volumes and im-
provement of left ventricular ejection fraction (video 5).
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